Clinical Tutorials
A course-length track for physicians and well-informed patients: how a genomic workup is produced and read, how disease processes are detected years early, and what the evidence actually supports.
Every tutorial in this track is independently reviewed for clinical accuracy by a second model before publication.
Reading a Genome
What a 30× Whole Genome Sequence Actually Is — and What It Still Cannot Tell You
What a clinical 30× genome measures, why coverage matters more than the headline number, how it compares with arrays and exomes, and which conditions still need a dedicated test after a normal report.
From Blood Draw to Variant List: What the Genomic Pipeline Does, and Where It Fails Quietly
A clinician's account of how a DNA sample becomes a classified variant list, why millions of variants is normal, where errors and false negatives come from, and what to ask the laboratory when a result does not fit the patient.
Pathogenic, Benign, or Uncertain: How a Variant Gets Its Verdict — and What Each Verdict Licenses
How a germline variant earns its classification, how much a ClinVar entry deserves to be trusted, why a pathogenic variant is not a diagnosis, and how to handle a variant of uncertain significance without acting on it or losing track of it.
The 94th Percentile Is Not a 94% Risk: Reading Polygenic Scores in Cardiovascular Prevention
How a polygenic score is built, why a percentile is a rank and not a probability, why ancestry can make a score misleading, and how a high or low result legitimately changes the timing and intensity of prevention without changing a diagnosis.
Reading a Pharmacogenomic Report: The Gene–Drug Pairs That Actually Change a Prescription
How to turn a pharmacogenomic result into a prescribing decision: what a metabolizer label means, which gene–drug pairs have the evidence to act on, why concurrent drugs can override a genotype, and where to look up the recommended action.
HLA Typing in Practice: The Results That Prevent a Severe Drug Reaction — and the Ones That Only Rule Out Disease
Which HLA results prevent severe hypersensitivity to abacavir, carbamazepine, and allopurinol, how to read celiac, HLA-B27, and narcolepsy associations without over-reading them, and when a genome-derived HLA call needs a dedicated laboratory test before anyone acts on it.
SNPs and SNP Panels: Reading a Curated Variant Report Without Over-Reading It
A clinical guide to SNP-based genotyping: why most common variants do nothing, where panels are useful (pharmacogenomics, HLA types, polygenic scores), why a negative panel is not a negative result, and how to counsel on the aggregate picture rather than a single row.
Multi-Omic Integration
Genotype Sets the Hand, Bloodwork Shows How It Is Being Played: Pairing Genetic Risk With Movable Cardiometabolic Markers
A genetic result sets the starting odds. Measured, movable blood markers show whether those odds are being realized and whether treatment is changing them. This tutorial covers which tests to add beyond a standard panel and why a value within the reference range is not the same as an optimal one.
Imaging the Longevity Workup: What Calcium Scoring, CCTA, Whole-Body MRI, DEXA and CPET Each Buy — and What Each Costs
What each study in a longevity imaging workup shows, what it cannot see, what it sets in motion downstream, and how to order it against pre-test probability rather than ordering everything.
When the Layers Agree: Reading Stool and Broad Protein Panels Alongside the Genome
What stool tests and broad protein panels actually measure, how much weight each deserves today, and why agreement across independent layers is the strongest finding a longevity workup produces.
The Precision Longevity Workup, in the Order It Should Actually Be Run
Run the advanced longevity workup in the order that lets each layer answer what the previous one couldn't, from 30x genome to proteomics. Each named test carries a stated confidence, and the results become one prioritized plan and an honest projection.
The Five Horsemen
Insulin Resistance in the Compensated Phase: Reading the Decade Before Type 2 Diabetes
Fasting glucose and HbA1c stay normal for years while insulin climbs. This tutorial covers how to detect the compensated phase on ordinary bloodwork and imaging, how to stage fatty liver without a biopsy, and how to build a plan that treats the cause rather than the glucose.
Plaque as Cumulative Exposure: apoB, Lp(a), Imaging and Inherited Risk in the Patient Whose Cholesterol Looks Fine
Why atherosclerosis is an accumulated dose of apoB particles rather than a risk percentage at sixty, and how particle count, Lp(a), imaging, genetics and the lipid-lowering options combine into a decision about when to start.
The Third Horseman: Reading Alzheimer's and Parkinson's Risk Two Decades Before Symptoms
Neurodegeneration is a midlife disease that is diagnosed late. This tutorial covers where the Alzheimer's cascade can be modified, how to counsel an APOE4 carrier, how to read plasma p-tau217, NfL and GFAP, the risk factors worth working through, the Parkinson's prodrome, and what anti-amyloid antibodies offer and cost.
Cancer as an Evolutionary Process: Inherited Risk, Modifiable Risk, and Which Screens Have Mortality Evidence
How cancer arises through mutation and selection, which inherited syndromes change management now, why detection evidence is not mortality evidence, and which prevention claims have survived randomized trials.
Autoimmunity Before It Declares: Tolerance, Triggers and the Pre-Clinical Antibody Window
How the immune system learns not to attack the body, how genes and environmental triggers break that tolerance, and how to read and order autoantibodies during the years when risk is visible but disease has not yet appeared.
The Hallmarks of Aging
The Primary Hallmarks of Aging: Which Damage You Can Actually Measure
Genomic instability, telomere attrition, epigenetic drift, failing protein quality control and impaired autophagy, read for consequence: which can be measured in a patient, which interventions plausibly reach them, and where the human evidence stops.
Nutrient Sensing, Mitochondria and Senescence: Reading the Antagonistic Hallmarks in a Real Patient
Three aging hallmarks begin as protective responses and become harmful when they stay switched on. This tutorial covers what can be measured in a patient today and how far the human evidence for rapamycin, metformin, NAD precursors and senolytics actually goes.
The Integrative Hallmarks of Aging: Reading Frailty, Inflammation and Regenerative Decline in the Consultation Room
How the integrative hallmarks of aging produce the frailty and multimorbidity seen in clinic, how to measure them with a dynamometer, a stopwatch and a routine blood panel, and why structured training moves more of them at once than any drug or supplement.
The Omic Layers
Reading an Epigenetic Age Result: What the Number Is Worth
How methylation clocks are built, why the training target sets what a result means, and why measurement noise matters more than any other point when a patient reports that their biological age has fallen.
Proteome and Metabolome: Reading What Is Happening Now
Protein and metabolite measurements report what the body is doing now, not what it inherited. This tutorial covers what single proteins already decide in clinic, what broad protein panels and organ-age signals can and cannot claim, why metabolomics is hard to read, and why all of it is built for serial tracking rather than a single snapshot.
The Aging Immune System: Reading Inflammaging, Immunosenescence and the Immune Panel
How the adaptive immune system loses capacity with age, how chronic sterile inflammation feeds that loss, and how to read hs-CRP, the CD4:CD8 ratio and CMV serology. Interventions are ranked by the evidence behind them.
The Microbiome in Clinic: The Barrier, Butyrate, and What Actually Justifies an Action
How the intestinal barrier fails and drives systemic inflammation, which stool and microbiome findings warrant action today, how the interventions rank by evidence, and the drug–microbiome interactions to anticipate.
Mechanisms at Clinical Depth
Senescent Cells and Senolytics: A Clinician's Guide to Where the Evidence Actually Stops
What a senescent cell is, why it protects before it harms, and how a small number of them drive tissue disease. Also what the senolytic trials have and have not shown, and how to counsel a patient who wants to start a protocol.
Growth Versus Maintenance: Fasting, Protein and the Rapamycin Question
How food, especially protein, switches the body toward growth and how fasting and exercise switch it toward cellular maintenance. Covers what the human evidence shows, why muscle wins in the older sarcopenic patient, and what is and is not known about rapamycin and metformin.
Mitochondrial Function in the Clinic: Measuring Capacity, Recognizing Inherited Disease, and Ranking What Actually Works
Why there is no useful blood test for mitochondrial capacity but there is an excellent functional one, how to recognize inherited mitochondrial disease and refer it, and how the interventions for acquired dysfunction rank against each other, with aerobic training far ahead of every supplement.
NAD+ Precursors: Reading the Trial Evidence and Answering the Patient Who Asks
NAD+ declines with age mainly because consumption rises, not because production fails. This tutorial covers what precursor trials have and have not demonstrated, why IV NAD+ adds cost without a shown advantage, and what raises NAD+ without a purchase.
Frontier and Lifestyle Therapeutics
Prescribing Hormetic Stress: Sauna, Cold Immersion and the Doses the Human Studies Actually Used
What the sauna cohorts and cold-exposure trials actually tested, why a cold plunge after lifting works against the session, and who should do neither.
Hyperbaric Oxygen: Telling the Reimbursed Indications Apart from the Longevity Claims
How hyperbaric oxygen works, which indications rest on real evidence, what the telomere and cognition trials did and did not show, and how to counsel a patient weighing a 60-session course or a home soft chamber.
Therapeutic Peptides: Reading the Category from Approved Drug to Research Chemical
Where approved peptide medicines, off-label growth hormone secretagogues and unapproved tissue-repair peptides sit on the evidence spectrum, what the regulatory position means for sourcing, and how to answer a patient who asks about them.
Stem Cells and Exosomes: What Is Approved, What Is Actually Injected, and What the Trials Show
A clinical guide to what is injected under the stem cell label, why the cells mostly act through what they secrete rather than by becoming new tissue, where the approved therapies and controlled trials actually sit, and how to judge a clinic's claims.
Photobiomodulation: Which Indications Hold Up, and Whether the Device on the Bench Delivers a Dose
What red and near-infrared light is proposed to do in tissue, which indications rest on guidelines or randomized trials and which are still speculative, and how to judge whether a consumer panel delivers anything close to what a trial used.
Incretin Pharmacotherapy in Practice: What the Drugs Do, What the Trials Prove, and What the Weight Loss Is Made Of
How GLP-1 and dual-agonist drugs work, which cardiometabolic outcomes they and the other metabolic pillars have demonstrated, and how to manage lean-mass loss, gastrointestinal effects, peri-procedural risk and the weight regain that follows stopping.
Hormone Therapy in the Longevity Clinic: Replacement to Range, and the Line Beyond It
Menopausal hormone therapy after the WHI reinterpretation, a proper workup for low testosterone, subclinical thyroid results, and growth hormone, organized around one line: whether therapy restores a physiological range or goes beyond it.